How have cystic fibrosis patient outcomes changed in adults from 2011 to 2022?
Cystic fibrosis (CF) is a genetic condition that affects the lungs and other organs. Over the past decade, new medications called CFTR modulators have changed how CF is treated. For adults, outcomes such as lung function, body weight, and infection rates have improved significantly between 2011 and 2022. Registry data and clinical studies show that these gains are closely tied to the use of modulator therapies, especially the triple combination elexacaftor/tezacaftor/ivacaftor (ETI).
What the research says
A large registry study from a single adult CF center tracked outcomes from 2011 to 2022. Median lung function (measured as percent predicted FEV1) rose from 63.4% in 2011 to 78.8% in 2021. Body mass index (BMI) increased from 22.3 to 24.8 kg/m². The proportion of adults having more than one pulmonary exacerbation per year dropped from 39.7% to 19.5%, and the rate of Pseudomonas aeruginosa infection fell from 79% to 47%. The greatest improvements occurred after the introduction of ETI therapy 3.
A separate prospective study of 487 people with CF (average age 25 years) who started ETI for the first time found that after 6 months, lung function improved by 9.76 percentage points, respiratory symptoms improved by 20.4 points on a standard questionnaire, and sweat chloride (a measure of CFTR function) dropped by 41.7 mmol/L. BMI also increased significantly. These changes were larger in patients who had not used other modulators before 5.
During the COVID-19 pandemic, Australian registry data showed that lung function trends actually improved: from a mean annual decline of -0.13% before the pandemic to a mean improvement of 1.76% after. BMI trends also improved, and hospitalizations decreased. Virtual consultations increased from 8% to 47% 6. While this period overlaps with modulator use, the pandemic-related changes in care delivery may have contributed.
Not all research focuses on modulators. A narrative review found insufficient evidence for using a single CFTR modulator (monotherapy) in people with the common F508del mutation, suggesting that combination therapy is more effective 1. Another expert consensus document notes that N-acetylcysteine (NAC) may be useful as an adjunct in CF, but the main driver of improved outcomes in the last decade has been CFTR modulator therapy 2.
What to ask your doctor
- What CFTR modulator therapy is right for me based on my genetic mutation?
- How often should I have lung function tests and BMI checks to track my progress?
- Are there any new treatments or clinical trials that might benefit me?
- How can I manage pulmonary exacerbations and reduce their frequency?
- What role do airway clearance techniques and other supportive therapies play in my care?
This question is drawn from common patient questions about Infectious Disease and answered using cited medical research. We do not provide individualized advice.